For 2015 the consensus of the earnings per share of Actelion is at profit of 5,67 Switzerland Franc. Based on this the price/earnings-ratio equals 24,22.
The consensus of the dividends per share is at 1,5 Switzerland Franc.Consequently the dividend return is around 1,09 percent. On average the stocks in this sector yield a dividend return of around 0,54 percent.
The stocks Mithra, Kiadis and Shire in the sector pharmaceutical sector have the most buy recommendations. The 3 most recent recommendations for the pharmaceutical sector were provided by HSBC (buy, 155,00 Switzerland Franc), Berenberg (hold, 143,00 Switzerland Franc) and Deutsche Bank (hold, 180,00 Switzerland Franc).
Actelion's book value/price equals 0,13. The pharmaceutical company now trades at a Shiller PE of 20.22. The stock now trades at 137,30 Switzerland Franc. This equals 27 times the 2014's earnings per share.